Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront

Ayisha Sharma

News Reporter

Novartis is spending $55 million on global rights to Kyorin Pharmaceutical’s preclinical drug for inflammatory diseases in a deal that comes almost two decades after …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront

Ayisha Sharma

News Reporter

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Roche CEO warns that tariffs could impact dealmaking

Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge

Bristol Myers' transition moves forward as it raises 2025 revenue forecast

Thermo Fisher buckles up for US-China trade war, budgets $2B to ease impact

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

No­var­tis li­cens­es Ky­orin’s pre­clin­i­cal chron­ic hives can­di­date for $55M up­front

News Reporter

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

Novartis licenses Kyorin’s preclinical chronic hives candidate for $55M upfront